Literature DB >> 14666368

Variation in the FABP2 promoter affects gene expression: implications for prior association studies.

M L Formanack1, L J Baier.   

Abstract

AIMS/HYPOTHESIS: An Ala54Thr polymorphism in the FABP2 gene has previously been associated with insulin resistance and lipid oxidation rates in Pima Indians. Ala54Thr functionally alters the protein's ability to bind and transport dietary fatty acids. In the current report, we sought additional functional variation in FABP2 by sequencing putative regulatory regions.
METHODS: More than 1.2 Kb of the putative promoter of FABP2 was sequenced in 20 Pima subjects. Variations were genotyped in 84 additional Pima Indian subjects to assess haplotype combinations. Functional activities of variant and nonvariant promoters were compared in Caco-2 cells transfected with luciferase reporter constructs.
RESULTS: Seven variations were identified in the FABP2 promoter in Pima Indians. Genotypes of these variants were in complete concordance with each other, and were in complete concordance with Ala54Thr. Therefore, only two promoter alleles were observed in Pima Indians, an Ala54-associated promoter and a Thr54-associated promoter. In contrast, genotyping of these variants in Caucasian DNA showed multiple genotypic combinations. In vitro reporter assays indicated that the Thr54-associated promoter in Pima Indians resulted in a threefold reduction in promoter activity as compared to Ala54-associated promoter. CONCLUSION/
INTERPRETATION: Two functional variations exist in FABP2--the coding Ala54Thr and the variant promoter. In the Pima Indian population, but not the Caucasian population, these two functional variants are always carried on the same allele. Therefore, some of the in vivo phenotypic associations previously attributed to the Ala54Thr substitution, which alters binding characteristics of the protein, could instead be due to promoter variation, which alters expression levels.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14666368     DOI: 10.1007/s00125-003-1289-z

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  9 in total

1.  Codon-54 polymorphism of the fatty acid-binding protein 2 gene is associated with elevation of fasting and postprandial triglyceride in type 2 diabetes.

Authors:  A Georgopoulos; O Aras; M Y Tsai
Journal:  J Clin Endocrinol Metab       Date:  2000-09       Impact factor: 5.958

2.  Effects of an Ala54Thr polymorphism in the intestinal fatty acid-binding protein on responses to dietary fat in humans.

Authors:  R E Pratley; L Baier; D A Pan; A D Salbe; L Storlien; E Ravussin; C Bogardus
Journal:  J Lipid Res       Date:  2000-12       Impact factor: 5.922

3.  The polymorphism at codon 54 of the FABP2 gene increases fat absorption in human intestinal explants.

Authors:  E Levy; D Ménard; E Delvin; S Stan; G Mitchell; M Lambert; E Ziv; J C Feoli-Fonseca; E Seidman
Journal:  J Biol Chem       Date:  2001-08-03       Impact factor: 5.157

Review 4.  Fatty acid binding protein-2 gene variants and insulin resistance: gene and gene-environment interaction effects.

Authors:  Edward P Weiss; Michael D Brown; Alan R Shuldiner; James M Hagberg
Journal:  Physiol Genomics       Date:  2002-09-03       Impact factor: 3.107

5.  Detection of a promoter polymorphism in the gene of intestinal fatty acid binding protein (I-FABP).

Authors:  K Geschonke; M Klempt; N Lynch; S Schreiber; S Fenselau; J Schrezenmeir
Journal:  Ann N Y Acad Sci       Date:  2002-06       Impact factor: 5.691

6.  Variation in the FABP2 promoter alters transcriptional activity and is associated with body composition and plasma lipid levels.

Authors:  Coleen M Damcott; Eleanor Feingold; Susan P Moffett; M Michael Barmada; Julie A Marshall; Richard F Hamman; Robert E Ferrell
Journal:  Hum Genet       Date:  2003-03-13       Impact factor: 4.132

7.  A polymorphism in the human intestinal fatty acid binding protein alters fatty acid transport across Caco-2 cells.

Authors:  L J Baier; C Bogardus; J C Sacchettini
Journal:  J Biol Chem       Date:  1996-05-03       Impact factor: 5.157

8.  An amino acid substitution in the human intestinal fatty acid binding protein is associated with increased fatty acid binding, increased fat oxidation, and insulin resistance.

Authors:  L J Baier; J C Sacchettini; W C Knowler; J Eads; G Paolisso; P A Tataranni; H Mochizuki; P H Bennett; C Bogardus; M Prochazka
Journal:  J Clin Invest       Date:  1995-03       Impact factor: 14.808

9.  Solution structure of human intestinal fatty acid binding protein with a naturally-occurring single amino acid substitution (A54T) that is associated with altered lipid metabolism.

Authors:  Fengli Zhang; Christian Lücke; Leslie J Baier; James C Sacchettini; James A Hamilton
Journal:  Biochemistry       Date:  2003-06-24       Impact factor: 3.162

  9 in total
  4 in total

Review 1.  Liver fatty acid-binding protein and obesity.

Authors:  Barbara P Atshaves; Gregory G Martin; Heather A Hostetler; Avery L McIntosh; Ann B Kier; Friedhelm Schroeder
Journal:  J Nutr Biochem       Date:  2010-11       Impact factor: 6.048

2.  Copy number variation of individual cattle genomes using next-generation sequencing.

Authors:  Derek M Bickhart; Yali Hou; Steven G Schroeder; Can Alkan; Maria Francesca Cardone; Lakshmi K Matukumalli; Jiuzhou Song; Robert D Schnabel; Mario Ventura; Jeremy F Taylor; Jose Fernando Garcia; Curtis P Van Tassell; Tad S Sonstegard; Evan E Eichler; George E Liu
Journal:  Genome Res       Date:  2012-02-02       Impact factor: 9.043

3.  The effect of FABP2 promoter haplotype on response to a diet with medium-chain triacylglycerols.

Authors:  Diana Rubin; Ulf Helwig; Maria Pfeuffer; Annegret Auinger; Andreas Ruether; Dennis Matusch; Stephanie Darabaneanu; Sandra Freitag-Wolf; Michael Nothnagel; Stefan Schreiber; Jürgen Schrezenmeir
Journal:  Genes Nutr       Date:  2012-01-24       Impact factor: 5.523

4.  Polymorphisms in fatty acid binding protein 5 show association with type 2 diabetes.

Authors:  Liming Bu; Lorena M Salto; Kevin J De Leon; Marino De Leon
Journal:  Diabetes Res Clin Pract       Date:  2011-02-01       Impact factor: 5.602

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.